Roughly four in ten patients drop GLP-1 drugs within a year over side effects, and pharma is betting a different hunger hormone can keep them on treatment.
Recap by typeshit. Post by Facebook on Facebook.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Quartz says four in ten patients stop GLP-1 drugs, and looks at a newer injection built around the reason they drop off.
Pooling 37 phase 3 trials and over 50,000 adults, researchers found each point of weight lost tracked with about 0.37 mmHg lower systolic pressure.
Loading…